• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks With Whale Alerts In Today's Session

    5/9/24 1:35:23 PM ET
    $ALNY
    $BLUE
    $BMY
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALNY alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    MRNA PUT SWEEP BULLISH 05/17/24 $122.00 $36.6K 148 2.3K
    ALNY PUT SWEEP BEARISH 07/19/24 $140.00 $26.5K 405 390
    HUM CALL TRADE BULLISH 05/17/24 $340.00 $33.8K 361 352
    MCK PUT SWEEP BEARISH 05/17/24 $555.00 $46.9K 1 260
    CORT CALL SWEEP BEARISH 06/21/24 $22.00 $69.3K 7 186
    NVO CALL SWEEP BULLISH 06/21/24 $135.00 $45.5K 3.5K 74
    BMY PUT TRADE BEARISH 06/21/24 $49.00 $25.2K 1.2K 60
    THC PUT SWEEP NEUTRAL 08/16/24 $120.00 $28.9K 26 50
    BLUE PUT SWEEP BULLISH 01/17/25 $15.00 $68.8K 101 50
    PODD CALL SWEEP BULLISH 06/21/24 $170.00 $28.7K 70 39

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For MRNA (NASDAQ:MRNA), we notice a put option sweep that happens to be bullish, expiring in 8 day(s) on May 17, 2024. This event was a transfer of 122 contract(s) at a $122.00 strike. This particular put needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $300.0 per contract. There were 148 open contracts at this strike prior to today, and today 2346 contract(s) were bought and sold.

    • Regarding ALNY (NASDAQ:ALNY), we observe a put option sweep with bearish sentiment. It expires in 71 day(s) on July 19, 2024. Parties traded 18 contract(s) at a $140.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $1482.0 per contract. There were 405 open contracts at this strike prior to today, and today 390 contract(s) were bought and sold.

    • Regarding HUM (NYSE:HUM), we observe a call option trade with bullish sentiment. It expires in 8 day(s) on May 17, 2024. Parties traded 100 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $33.8K, with a price of $338.0 per contract. There were 361 open contracts at this strike prior to today, and today 352 contract(s) were bought and sold.

    • For MCK (NYSE:MCK), we notice a put option sweep that happens to be bearish, expiring in 8 day(s) on May 17, 2024. This event was a transfer of 87 contract(s) at a $555.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $46.9K, with a price of $540.0 per contract. There were 1 open contracts at this strike prior to today, and today 260 contract(s) were bought and sold.

    • For CORT (NASDAQ:CORT), we notice a call option sweep that happens to be bearish, expiring in 43 day(s) on June 21, 2024. This event was a transfer of 102 contract(s) at a $22.00 strike. This particular call needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $69.3K, with a price of $680.0 per contract. There were 7 open contracts at this strike prior to today, and today 186 contract(s) were bought and sold.

    • For NVO (NYSE:NVO), we notice a call option sweep that happens to be bullish, expiring in 43 day(s) on June 21, 2024. This event was a transfer of 186 contract(s) at a $135.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $45.5K, with a price of $244.0 per contract. There were 3523 open contracts at this strike prior to today, and today 74 contract(s) were bought and sold.

    • Regarding BMY (NYSE:BMY), we observe a put option trade with bearish sentiment. It expires in 43 day(s) on June 21, 2024. Parties traded 52 contract(s) at a $49.00 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $485.0 per contract. There were 1294 open contracts at this strike prior to today, and today 60 contract(s) were bought and sold.

    • For THC (NYSE:THC), we notice a put option sweep that happens to be neutral, expiring in 99 day(s) on August 16, 2024. This event was a transfer of 50 contract(s) at a $120.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.9K, with a price of $579.0 per contract. There were 26 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold.

    • For BLUE (NASDAQ:BLUE), we notice a put option sweep that happens to be bullish, expiring in 253 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $15.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $68.8K, with a price of $1377.0 per contract. There were 101 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold.

    • Regarding PODD (NASDAQ:PODD), we observe a call option sweep with bullish sentiment. It expires in 43 day(s) on June 21, 2024. Parties traded 15 contract(s) at a $170.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $1924.0 per contract. There were 70 open contracts at this strike prior to today, and today 39 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY
    $BLUE
    $BMY
    $CORT

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Novo Nordisk A/S
    $NVO
    2/24/2026Buy → Hold
    Kepler
    Novo Nordisk A/S
    $NVO
    2/24/2026Overweight → Neutral
    Analyst
    Novo Nordisk A/S
    $NVO
    2/23/2026Buy → Hold
    Deutsche Bank
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    More analyst ratings

    $ALNY
    $BLUE
    $BMY
    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novo Nordisk A/S downgraded by TD Cowen with a new price target

    TD Cowen downgraded Novo Nordisk A/S from Buy to Hold and set a new price target of $42.00

    3/10/26 8:39:23 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Novo Nordisk A/S from Underweight to Equal-Weight and set a new price target of $40.00

    3/3/26 8:17:03 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S downgraded by Goldman with a new price target

    Goldman downgraded Novo Nordisk A/S from Buy to Neutral and set a new price target of $41.00

    3/2/26 8:56:43 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Information Officer Arbour Paola M sold $1,549,795 worth of shares (6,500 units at $238.43), decreasing direct ownership by 18% to 29,291 units (SEC Form 4)

    4 - TENET HEALTHCARE CORP (0000070318) (Issuer)

    3/13/26 8:00:03 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    SEC Form 4 filed by President, RayzeBio Org. Hickey Benjamin

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    3/12/26 4:24:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Strategy Officer Shibutani Hiroshi Chris

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    3/12/26 4:23:48 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    SEC Filings

    View All

    Insulet Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    3/12/26 4:06:56 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Humana Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - HUMANA INC (0000049071) (Filer)

    3/9/26 4:22:23 PM ET
    $HUM
    Medical Specialities
    Health Care

    SEC Form 144 filed by Tenet Healthcare Corporation

    144 - TENET HEALTHCARE CORP (0000070318) (Subject)

    3/9/26 1:08:26 PM ET
    $THC
    Hospital/Nursing Management
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Minogue Michael R bought $499,847 worth of shares (2,030 units at $246.23) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/26/26 7:05:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    President and CEO Mcevoy Ashley bought $1,029,205 worth of shares (4,300 units at $239.35), increasing direct ownership by 45% to 13,916 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/23/26 8:14:32 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.

    Medical Device Correction impacts only specific lots of Omnipod® 5 Pods Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost All other Omnipod® 5 Pods and Omnipod® products remain safe to use Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company") today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use. Insulet identified that certain Pods from specific lots

    3/12/26 4:05:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Continuous Glucose Monitoring on the Rise Among Medicare Advantage Members with Type 2 Diabetes

    Study by Humana Healthcare Research and Yale School of Medicine researcher reveals significant increase in CGM usage, particularly among older adults with chronic health conditions. A new study published in the current issue of the Journal of Managed Care & Specialty Pharmacy (JMCP)—conducted by a Humana Healthcare Research team and Dr. Joseph S. Ross of the Yale School of Medicine—reveals a notable increase in the use of continuous glucose monitors (CGMs) among Medicare Advantage members with type 2 diabetes from 2021 to 2023. The study also compared the demographic and clinical characteristics of members with type 2 diabetes who used CGMs with those who did not in 2023, finding that t

    3/12/26 9:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes

    Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve outcomes, and redefine user and clinician experience Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has shared new clinical evidence related to the development of its first fully closed-loop (FCL)A automated insulin delivery (AID) system for type 2 diabetes. "Developing and bringing to market a fully closed-loop AID system for people with type 2 diabetes—one that delivers therapy effortl

    3/11/26 4:01:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    Leadership Updates

    Live Leadership Updates

    View All

    McKesson Announces Planned CFO Transition

    Britt Vitalone announces retirement, Kenny Cheung named as successor McKesson Corporation (NYSE:MCK) today announced Britt Vitalone, Executive Vice President and Chief Financial Officer (CFO), has elected to retire after a successful and distinguished 20-year career with the company, including more than eight years as CFO. Looking ahead, Kenny Cheung will join McKesson as Executive Vice President and CFO, effective May 29, 2026. "Britt is an exceptional partner and leader. He has been instrumental in advancing the company's financial performance, engaging with shareholders, and instilling a culture of financial discipline," said Brian Tyler, Chief Executive Officer, McKesson Corporation

    3/5/26 8:10:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ryder System, Inc. Elects Tammy Romo to Its Board of Directors

    The board of directors of Ryder System, Inc. (NYSE:R) today announces the appointment of Tammy Romo, 63, to its board, effective January 5, 2026. Romo will serve as a member of the Audit and Finance Committees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219927656/en/Ryder appoints Tammy Romo to its board of directors, effective January 5, 2026. "The board nominated Tammy as a director for her impressive results-oriented leadership style, proven ability to provide strategic oversight in complex public company settings, and her deep transportation expertise," says Ryder Chairman and CEO Robert Sanchez. "Tammy's experience in

    12/19/25 6:55:00 AM ET
    $R
    $THC
    Rental/Leasing Companies
    Consumer Discretionary
    Hospital/Nursing Management
    Health Care

    $ALNY
    $BLUE
    $BMY
    $CORT
    Financials

    Live finance-specific insights

    View All

    McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences

    McKesson Corporation (NYSE:MCK) will release its fourth quarter fiscal 2026 financial results after market close on Thursday, May 7, 2026. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Mr. Vitalone will be participating in Leerink Partners Global Healthcare Conference and Barclays Global Healthcare Conference on Wednesday, March 11, 2026. Mr. Vitalone will also participate in the BofA Securities 2026 Healthcare Conference in May 2026. McKesson Corporation has reaffirmed fiscal 2026 full year outlook as previously issued on Febru

    3/6/26 8:00:00 AM ET
    $MCK
    Other Pharmaceuticals
    Health Care

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit u

    3/2/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Feb. 25, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Ashley Mastronardi delivers the pre-market update on February 25thEquities are higher Wednesday morning as Nvidia prepares to release its fourth quarter earnings after market close.MSCI Emerging Markets Index Options and MSCI EAFE Index Options are set to begin trading on NYSE Arca Options today under the ticker symbols MXEF and MXEADynatrace (NYSE:DT) CEO Rick McConnell will

    2/25/26 8:55:00 AM ET
    $BMY
    $DT
    $ICE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    $ALNY
    $BLUE
    $BMY
    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

    11/14/24 4:39:36 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by bluebird bio Inc.

    SC 13G/A - bluebird bio, Inc. (0001293971) (Subject)

    11/14/24 4:27:32 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenet Healthcare Corporation

    SC 13G/A - TENET HEALTHCARE CORP (0000070318) (Subject)

    11/14/24 4:17:18 PM ET
    $THC
    Hospital/Nursing Management
    Health Care